Roger Longman
Since its formation in the fall of 2007, Flexion Therapeutics Inc. has apparently had no trouble getting Big Pharmas...
Flexion Exploits Big Pharma as Discovery Supplier
Listen to this article
Big Pharma, unable to exploit its own research productivity, is increasingly seeing itself as a supplier of discovery assets. That's bad news for discovery-based biotech, but good news for companies with a talent for faster, more predictable development capabilities. Since its formation in the fall of 2007, Flexion Therapeutics has apparently had no trouble getting Big Pharmas to let them review their shelved compounds, 130 or so of them from eight to 10 companies. Flexion, built around Lilly's fast-to-proof-of-concept strategy, is attempting to take advantage of the trend; it's in-licensed five products from three Big Pharmas.
Candid conversations with C-suite leaders.
More from In Vivo Archive
- In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
- • By
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
- • By
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
